TG2 siRNA-DOPC

TG2 siRNA-DOPC is a **gene silencing therapy** consisting of a small interfering RNA (siRNA) specifically targeting the messenger RNA of **tissue transglutaminase 2 (TG2)**, formulated within neutral liposomes made of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)[1]. This formulation enables **systemic delivery of siRNA** in vivo to reduce TG2 expression in cancer cells. TG2 is a multifunctional enzyme implicated in tumor cell invasion, metastasis, chemoresistance, and survival; its overexpression correlates with worse prognosis in ovarian and other cancers. By silencing TG2, TG2 siRNA-DOPC reduces tumor cell proliferation, angiogenesis, metastasis, and enhances cancer cell apoptosis. In preclinical models, it showed significant anti-tumor activity both alone and synergistically with chemotherapeutic agents such as docetaxel[1][2]. The drug is primarily being studied for ovarian cancer and also for pancreatic cancer[1][2].

Other names

TG2 small interfering RNA-DOPCTG-2 small interfering RNA-DOPCTG 2 small interfering RNA-DOPCtissue transglutaminase siRNA-DOPC